• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

特发性帕金森病中痴呆的演变:支持亚型划分的神经心理学和临床证据

The evolution of dementia in idiopathic Parkinson's disease: neuropsychological and clinical evidence in support of subtypes.

作者信息

Reid W G

机构信息

Department of Geriatric Medicine, University of Sydney, New South Wales, Australia.

出版信息

Int Psychogeriatr. 1992;4 Suppl 2:147-60.

PMID:1288660
Abstract

One hundred and seven newly diagnosed, untreated patients with Parkinson's disease (PD) were divided into two groups according to their age at reported onset of symptoms. Of these, 79 patients were under age 70 (early-onset) and 28 patients were age 70 and over (late-onset). The group of 50 control subjects comprised spouses, friends of the PD patients, and community volunteers. The patients were participants in a multicenter drug study of Parkinson's disease. Each had received a detailed neurological and neuropsychological assessment in the baseline placebo phases of the study. Thirty-4 patients with early-onset and 12 patients with late-onset were reassessed 3 years after treatment with low-dose levodopa, with bromocriptine, or with a combination of the two drugs. The results of the baseline phase of the study revealed that 8% of the early-onset group and 32% of the late-onset group were classified as demented. The 3-year follow-up revealed that the prevalence of dementia had increased to 17% in the early-onset group and to 83% in the late-onset group. This study confirms that at least two distinct subtypes of Parkinson's disease exist. The subtypes differ both clinically and neuropsychologically. The age at onset of symptoms is a critical determinant of the rate and type of cognitive decline in Parkinson's disease.

摘要

107名新诊断的、未经治疗的帕金森病(PD)患者根据报告的症状发作年龄分为两组。其中,79名患者年龄在70岁以下(早发型),28名患者年龄在70岁及以上(晚发型)。50名对照受试者包括PD患者的配偶、朋友和社区志愿者。这些患者参与了一项帕金森病的多中心药物研究。在研究的基线安慰剂阶段,每位患者都接受了详细的神经学和神经心理学评估。34名早发型患者和12名晚发型患者在接受低剂量左旋多巴、溴隐亭或两种药物联合治疗3年后进行了重新评估。研究基线阶段的结果显示,早发型组中8%的患者和晚发型组中32%的患者被归类为痴呆。3年随访显示,早发型组痴呆患病率增至17%,晚发型组增至83%。这项研究证实,帕金森病至少存在两种不同的亚型。这些亚型在临床和神经心理学方面都有所不同。症状发作年龄是帕金森病认知衰退速度和类型的关键决定因素。

相似文献

1
The evolution of dementia in idiopathic Parkinson's disease: neuropsychological and clinical evidence in support of subtypes.特发性帕金森病中痴呆的演变:支持亚型划分的神经心理学和临床证据
Int Psychogeriatr. 1992;4 Suppl 2:147-60.
2
Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study).帕金森病相关痴呆:一项长达 20 年的神经心理学研究(悉尼多中心研究)。
J Neurol Neurosurg Psychiatry. 2011 Sep;82(9):1033-7. doi: 10.1136/jnnp.2010.232678. Epub 2011 Feb 18.
3
The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years.悉尼帕金森病多中心研究:头3年的报告
J Neurol Neurosurg Psychiatry. 1989 Mar;52(3):324-8. doi: 10.1136/jnnp.52.3.324.
4
Clinical observations in early and late onset Parkinson's disease.早发型和晚发型帕金森病的临床观察
Funct Neurol. 1991 Apr-Jun;6(2):145-9.
5
Method of addition of bromocriptine to the drug regime of patients with advanced Parkinson's disease.在晚期帕金森病患者的药物治疗方案中添加溴隐亭的方法。
Can J Neurol Sci. 1981 Feb;8(1):31-4. doi: 10.1017/s0317167100042803.
6
Nationwide multicenter prospective study on the long-term effects of bromocriptine for Parkinson's disease. Final report of a ten-year follow-up.溴隐亭治疗帕金森病长期疗效的全国多中心前瞻性研究。十年随访的最终报告。
Eur Neurol. 1997;38 Suppl 2:37-49. doi: 10.1159/000113482.
7
Levodopa-induced regional cerebral blood flow changes in normal volunteers and patients with Parkinson's disease. Lack of correlation with clinical or neuropsychological improvements.左旋多巴对正常志愿者和帕金森病患者局部脑血流的影响。与临床或神经心理学改善无关。
Mov Disord. 1987;2(4):279-89. doi: 10.1002/mds.870020405.
8
Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.盐酸多奈哌齐与左旋多巴/卡比多巴联合用于帕金森病患者:多次口服给药后药代动力学变化及安全性评估
Br J Clin Pharmacol. 2004 Nov;58 Suppl 1(Suppl 1):41-9. doi: 10.1111/j.1365-2125.2004.01799.x.
9
The natural history of treated Parkinson's disease in an incident, community based cohort.在一个以社区为基础的偶发性队列中,治疗帕金森病的自然史。
J Neurol Neurosurg Psychiatry. 2011 Oct;82(10):1112-8. doi: 10.1136/jnnp.2011.240366. Epub 2011 May 18.
10
Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.帕金森病中速释与控释卡比多巴/左旋多巴的比较。一项多中心5年研究。CR首次研究组。
Eur Neurol. 1997;37(1):23-7. doi: 10.1159/000117399.

引用本文的文献

1
Profile of cognitive impairment in late-stage Parkinson's disease.晚期帕金森病认知障碍特征。
Brain Behav. 2022 Apr;12(4):e2537. doi: 10.1002/brb3.2537. Epub 2022 Mar 7.
2
Screening Mild and Major Neurocognitive Disorders in Parkinson's Disease.帕金森病中轻度和重度神经认知障碍的筛查
Behav Neurol. 2015;2015:983606. doi: 10.1155/2015/983606. Epub 2015 May 19.
3
Cognitive impairments in progression of Parkinson's disease.帕金森病进展中的认知障碍。
Neurosci Behav Physiol. 2010 Jan;40(1):61-7. doi: 10.1007/s11055-009-9223-6.